Symbols

PLX

Protalix·AMEX

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 2

Consensus Rating "Strong Buy"

Significant Revenue Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PLX

Protalix Biotherapeutics, Inc.

A biopharmaceutical company that uses plant cell technology to produce recombinant proteins

Industry

Biological Technology

Established Date

Listing Date

03/12/2007

Exchange

American Stock Exchange

Full-time Employees

226

Fiscal Year Ends

12-31

Website

www.protalix.com

Security Type

Common stock

Office address

2 University Plaza , Suite 100 , Hackensack , NJ 07601

Business

Focus on the development and commercialization of recombinant therapeutic proteins with the company's proprietary ProCellEx protein expression system.

Introduction

Protalix Biotherapeutics, Inc., was originally incorporated in Florida in April 1992 and re-incorporated in Delaware in March 2016. The Company is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases using its proprietary plant cell protein expression system, ProCellEx. It has two approved products, Elelyso for Gaucher disease and Elfabrio for Fabry disease, commercialized through partnerships with Pfizer and Casey, respectively.

Company Financials

EPS

PLX has released its 2025 Q4 earnings. EPS was reported at -0.06, versus the expected 0.01, missing expectations. The chart below visualizes how PLX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PLX has released its 2025 Q4 earnings report, with revenue of 9.12M, reflecting a YoY change of -49.93%, and net profit of -5.50M, showing a YoY change of -184.76%. The Sankey diagram below clearly presents PLX's revenue sources and cost distribution.